ELOCTATE 500
Country: Israel
Language: English
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
COAGULATION FACTOR VIII
Available from:
SANOFI - AVENTIS ISRAEL LTD
ATC code:
B02BD05
Pharmaceutical form:
POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
Composition:
COAGULATION FACTOR VIII 500 IU
Administration route:
I.V
Prescription type:
Required
Manufactured by:
BIOGEN IDEC LIMITED , UK
Therapeutic area:
COAGULATION FACTOR VII
Therapeutic indications:
ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children 12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for:• Control and prevention of bleeding episodes.• Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• Perioperative management (surgical prophylaxis).ELOCTATE is not indicated for the treatment of von Willebrand disease.
Authorization date:
2017-01-09
